78 related articles for article (PubMed ID: 8313361)
1. Immunogenicity in rabbits and mice of an antibody-chelate conjugate: comparison of (S) and (R) macrocyclic enantiomers and an acyclic chelating agent.
Watanabe N; Goodwin DA; Meares CF; McTigue M; Chaovapong W; Ransone CM; Renn O
Cancer Res; 1994 Feb; 54(4):1049-54. PubMed ID: 8313361
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent.
Deshpande SV; DeNardo SJ; Kukis DL; Moi MK; McCall MJ; DeNardo GL; Meares CF
J Nucl Med; 1990 Apr; 31(4):473-9. PubMed ID: 2324823
[TBL] [Abstract][Full Text] [Related]
3. Antibody responses to macrocycles in lymphoma.
DeNardo GL; Mirick GR; Kroger LA; O'Donnell RT; Meares CF; DeNardo SJ
J Nucl Med; 1996 Mar; 37(3):451-6. PubMed ID: 8772643
[TBL] [Abstract][Full Text] [Related]
4. The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier molecule.
Perico ME; Chinol M; Nacca A; Luison E; Paganelli G; Canevari S
J Nucl Med; 2001 Nov; 42(11):1697-703. PubMed ID: 11696642
[TBL] [Abstract][Full Text] [Related]
5. Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice.
Adams GP; DeNardo SJ; Deshpande SV; DeNardo GL; Meares CF; McCall MJ; Epstein AL
Cancer Res; 1989 Apr; 49(7):1707-11. PubMed ID: 2493983
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from benzyl-EDTA chelate in vivo.
Deshpande SV; Subramanian R; McCall MJ; DeNardo SJ; DeNardo GL; Meares CF
J Nucl Med; 1990 Feb; 31(2):218-24. PubMed ID: 2107283
[TBL] [Abstract][Full Text] [Related]
7. Development of ELISA for detection of mercury based on specific monoclonal antibodies against mercury-chelate.
Zhang Y; Li X; Liu G; Wang Z; Kong T; Tang J; Zhag P; Yang W; Li D; Liu L; Xie G; Wang J
Biol Trace Elem Res; 2011 Dec; 144(1-3):854-64. PubMed ID: 21437665
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
DeNardo GL; Kroger LA; Meares CF; Richman CM; Salako Q; Shen S; Lamborn KR; Peterson JJ; Miers LA; Zhong GR; DeNardo SJ
Clin Cancer Res; 1998 Oct; 4(10):2483-90. PubMed ID: 9796981
[TBL] [Abstract][Full Text] [Related]
9. Suppression of human anti-mouse idiotypic antibody responses in hu-PBL-SCID mice.
Bitoh S; Lang GM; Sehon AH
Hum Antibodies Hybridomas; 1993 Jul; 4(3):144-51. PubMed ID: 8357958
[TBL] [Abstract][Full Text] [Related]
10. Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics.
DeNardo SJ; DeNardo GL; DeNardo DG; Xiong CY; Shi XB; Winthrop MD; Kroger LA; Carter P
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3213s-3218s. PubMed ID: 10541366
[TBL] [Abstract][Full Text] [Related]
11. Identification of important residues in metal-chelate recognition by monoclonal antibodies.
Delehanty JB; Jones RM; Bishop TC; Blake DA
Biochemistry; 2003 Dec; 42(48):14173-83. PubMed ID: 14640685
[TBL] [Abstract][Full Text] [Related]
12. Preparation of specific monoclonal antibodies (MAbs) against heavy metals: MAbs that recognize chelated cadmium ions.
Zhu X; Xu L; Lou Y; Yu H; Li X; Blake DA; Liu F
J Agric Food Chem; 2007 Sep; 55(19):7648-53. PubMed ID: 17715887
[TBL] [Abstract][Full Text] [Related]
13. Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody.
Lees A; Morris SC; Thyphronitis G; Holmes JM; Inman JK; Finkelman FD
J Immunol; 1990 Dec; 145(11):3594-600. PubMed ID: 2246504
[TBL] [Abstract][Full Text] [Related]
14. Generation of group-specific antibodies against sulfonamides.
Cliquet P; Cox E; Haasnoot W; Schacht E; Goddeeris BM
J Agric Food Chem; 2003 Sep; 51(20):5835-42. PubMed ID: 13129281
[TBL] [Abstract][Full Text] [Related]
15. Selective antibodies to propranolol enantiomers produced from a new conjugate.
Sahui-Gnassi A; Pham-Huy C; Galons H; Warnet JM; Claude JR; Duc HT
Chirality; 1993; 5(6):448-54. PubMed ID: 8398604
[TBL] [Abstract][Full Text] [Related]
16. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity.
Kozak RW; Raubitschek A; Mirzadeh S; Brechbiel MW; Junghans RP; Gansow OA; Waldmann TA
Cancer Res; 1989 May; 49(10):2639-44. PubMed ID: 2785435
[TBL] [Abstract][Full Text] [Related]
17. Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides.
Xu LC; Nakayama M; Harada K; Kuniyasu A; Nakayama H; Tomiguchi S; Kojima A; Takahashi M; Ono M; Arano Y; Saji H; Yao Z; Sakahara H; Konishi J; Imagawa Y
Bioconjug Chem; 1999; 10(1):9-17. PubMed ID: 9893958
[TBL] [Abstract][Full Text] [Related]
18. Modulation by adjuvants and carriers of the immunogenicity in xenogeneic hosts of mouse anti-idiotypic monoclonal antibody MK2-23, an internal image of human high molecular weight-melanoma associated antigen.
Chen ZJ; Yang H; Liu CC; Hirai S; Ferrone S
Cancer Res; 1993 Jan; 53(1):112-9. PubMed ID: 8416734
[TBL] [Abstract][Full Text] [Related]
19. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.
Kukis DL; DeNardo GL; DeNardo SJ; Mirick GR; Miers LA; Greiner DP; Meares CF
Cancer Res; 1995 Feb; 55(4):878-84. PubMed ID: 7850803
[TBL] [Abstract][Full Text] [Related]
20. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
